Coronary Heart Disease and Stroke Risk in Patients with Psoriasis: Retrospective Analysis



      Past studies suggest an association between psoriasis and the risk of developing coronary heart disease. The objectives of this study were to estimate the 10-year risks of coronary heart disease and stroke in patients with moderate to severe psoriasis, to compare risks between patients and the general population, and to determine whether risk profiles are affected by disease severity.


      Data were pooled from patients with moderate to severe psoriasis (Psoriasis Area and Severity Index [PASI] score10) who were enrolled in Phase II (M02-528) or Phase III trials (Comparative Study of HUMIRA vs Methotrexate vs Placebo In PsOriasis PatieNts[CHAMPION], Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL[REVEAL]) evaluating adalimumab. Risks of coronary heart disease and stroke were estimated using the Framingham risk score algorithm and a stroke risk function based on the Framingham Heart Study cohorts. To compare risks between patients with psoriasis and the general population, average population risks were imputed on the basis of age and gender. Wilcoxon rank-sum tests evaluated risk differences between patients with psoriasis and the general population and between patients with moderate psoriasis and patients with severe psoriasis.


      A total of 1591 patients were identified, including 1082 patients with PASI scores10 and ≤ 20 and 509 patients with PASI scores>20. Patients with PASI scores from 10 to 20 and PASI scores>20 had similar 10-year risks of coronary heart disease (12.3% and 12.2%; P=.49) and stroke (8.3% and 8.7%; P=.28). Compared with the general population, 10-year risks of patients with psoriasis were 28% greater for coronary heart disease (P<.001) and 11.8% greater for stroke (P=.02).


      Patients with moderate to severe psoriasis had increased risks of coronary heart disease and stroke compared with the general population.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Neimann A.L.
        • Shin D.B.
        • Wang X.
        • et al.
        Prevalence of cardiovascular risk factors in patients with psoriasis.
        J Am Acad Dermatol. 2006; 55: 829-835
        • Schmitt J.
        • Ford D.E.
        Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis—a structural equations modeling approach.
        Gen Hosp Psychiatry. 2007; 29: 134-140
        • Fowler J.F.
        • Duh M.S.
        • Rovba L.
        • et al.
        The impact of psoriasis on health care costs and patient work loss.
        J Am Acad Dermatol. 2008; 59: 772-780
        • McDonald C.J.
        Cardiovascular disease in psoriasis.
        J Invest Dermatol. 1989; 92: 646-647
        • Henseler T.
        • Christophers E.
        Disease concomitance in psoriasis.
        J Am Acad Dermatol. 1995; 32: 982-986
        • Pearce D.J.
        • Morrison A.E.
        • Higgins K.B.
        • et al.
        The comorbid state of psoriasis patients in a university dermatology practice.
        J Dermatolog Treat. 2005; 16: 319-323
        • Cohen A.D.
        • Sherf M.
        • Vidavsky L.
        • et al.
        Association between psoriasis and the metabolic syndrome.
        Dermatology. 2008; 216: 152-155
        • Trembath R.C.
        • Clough R.L.
        • Rosbotham J.L.
        • et al.
        Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis.
        Hum Mol Genet. 1997; 6: 813-820
        • Helms C.
        • Saccone N.L.
        • Cao L.
        • et al.
        Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR.
        Hum Genet. 2005; 118: 466-476
        • Gelfand J.M.
        • Troxel A.B.
        • Lewis J.D.
        • et al.
        The risk of mortality in patients with psoriasis: results from a population-based study.
        Arch Dermatol. 2007; 143: 1493-1499
        • Kremers H.M.
        • McEvoy M.T.
        • Dann F.J.
        • Gabriel S.E.
        Heart disease in psoriasis.
        J Am Acad Dermatol. 2007; 57: 347-354
        • Wakkee M.
        • Thio H.B.
        • Prens E.P.
        • et al.
        Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients.
        Atherosclerosis. 2007; 190: 1-9
        • Gottlieb A.B.
        • Chao C.
        • Dann F.
        Psoriasis comorbidities.
        J Dermatolog Treat. 2008; 19: 5-21
        • Kaye J.A.
        • Li L.
        • Jick S.S.
        Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis.
        Br J Dermatol. 2008; 159: 895-902
        • Wu Y.
        • Mills D.
        • Bala M.
        Psoriasis: cardiovascular risk factors and other disease comorbidities.
        J Drugs Dermatol. 2008; 7: 373-377
        • Gordon K.B.
        • Langley R.G.
        • Leonardi C.
        • et al.
        Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
        J Am Acad Dermatol. 2006; 55: 598-606
        • Shikiar R.
        • Heffernan M.
        • Langley R.G.
        • et al.
        Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
        J Dermatolog Treat. 2007; 18: 25-31
        • Saurat J.H.
        • Stingl G.
        • Dubertret L.
        • et al.
        • CHAMPION Study Investigators
        Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION).
        Br J Dermatol. 2008; 158: 558-566
        • Menter A.
        • Tyring S.K.
        • Gordon K.
        • et al.
        Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial.
        J Am Acad Dermatol. 2008; 58: 106-115
        • Haq I.U.
        • Ramsay L.E.
        • Yeo W.W.
        • et al.
        Is the Framingham risk function valid for northern European populations?.
        Heart. 1999; 81: 40-46
        • Wilson P.W.
        • D'Agostino R.B.
        • Levy D.
        • et al.
        Prediction of coronary heart disease using risk factor categories.
        Circulation. 1998; 97: 1837-1847
        • Linn S.
        • Fulwood R.
        • Carroll M.
        • et al.
        Serum total cholesterol: HDL cholesterol ratios in US white and black adults by selected demographic and socioeconomic variables (HANES II).
        Am J Public Health. 1991; 81: 1038-1043
        • D'Agostino R.B.
        • Wolf P.A.
        • Belanger A.J.
        • Kannel W.B.
        Stroke risk profile: adjustment for antihypertensive medication.
        Stroke. 1994; 25: 40-43
        • Nair D.
        • Carrigan T.P.
        • Curtin R.J.
        • et al.
        Association of coronary atherosclerosis detected by multislice computed tomography and traditional risk-factor assessment.
        Am J Cardiol. 2008; 102: 316-320
        • Gottlieb A.B.
        • Dann F.
        • Menter A.
        Psoriasis and the metabolic syndrome.
        J Drugs Dermatol. 2008; 7: 563-572
        • Grundy S.M.
        • Greenland P.
        • Herd A.
        • et al.
        Cardiovascular and risk factor evaluation of healthy American adults.
        Circulation. 1987; 75: 1340A-1362A
        • Gartside P.S.
        • Wang P.
        • Glueck C.J.
        Prospective assessment of coronary heart disease risk factors: the NHANES I epidemiologic follow-up study (NHEFS) 16-year follow-up.
        J Am Coll Nutr. 1998; 17: 263-269
        • World Health Organization
        BMI classification.
        (Accessed November 7)
        • Spratt K.A.
        Reducing the risk of coronary heart disease via lipid reduction.
        J Am Osteopath Assoc. 2004; 104: 9-13
        • Herron M.D.
        • Hinckley M.
        • Hoffman M.S.
        • et al.
        Impact of obesity and smoking on psoriasis presentation and management.
        Arch Dermatol. 2005; 141: 1527-1534
        • Naldi L.
        • Chatenoud L.
        • Linder D.
        • et al.
        Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study.
        J Invest Dermatol. 2005; 125: 61-67
        • Ogden C.L.
        • Carroll M.D.
        • McDowell M.A.
        • Flegal K.M.
        Obesity Among Adults in the United States—No Change Since 2003–2004.
        National Center for Health Statistics, Hyattsville, MD2007 (NCHS data brief no 1)
        • Mallbris L.
        • Akre O.
        • Granath F.
        • et al.
        Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients.
        Eur J Epidemiol. 2004; 19: 225-230
        • Maradit-Kremers H.
        • Crowson C.S.
        • Nicola P.J.
        • et al.
        Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.
        Arthritis Rheum. 2005; 52: 402-411
        • Warrington K.J.
        • Kent P.D.
        • Frye R.L.
        • et al.
        Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study.
        Arthritis Res Ther. 2005; 7: R984-R991
        • Malerba M.
        • Gisondi P.
        • Radaeli A.
        • et al.
        Plasma homocysteine and folate levels in patients with chronic plaque psoriasis.
        Br J Dermatol. 2006; 155: 1165-1169
        • McEwan P.
        • Williams J.E.
        • Griffiths J.D.
        • et al.
        Evaluating the performance of the Framingham risk equations in a population with diabetes.
        Diabet Med. 2004; 21: 318-323
        • Coleman R.L.
        • Stevens R.J.
        • Retnakaran R.
        • Holman R.R.
        Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.
        Diabetes Care. 2007; 30: 1292-1293
        • Rosamond W.
        • Flegal K.
        • Furie K.
        • et al.
        • American Heart Association Statistics Committee and Stroke Statistics Subcommittee
        Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
        Circulation. 2008; 117: e25-e146
        • Mokdad A.H.
        • Ford E.S.
        • Bowman B.A.
        • et al.
        Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.
        JAMA. 2003; 289: 76-79
        • Lloyd-Jones D.
        • Adams R.
        • Carnethon M.
        • et al.
        • American Heart Association Statistics Committee and Stroke Statistics Subcommittee
        Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
        Circulation. 2009; 119: e21-e181
        • Rosamond W.D.
        • Folsom A.R.
        • Chambless L.E.
        • et al.
        Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.
        Stroke. 1999; 30: 736-743
        • Centers for Disease Control and Prevention (CDC)
        Prevalence of disabilities and associated health conditions among adults--United States, 1999.
        MMWR Morb Mortal Wkly Rep. 2001; 50: 120-125
        • Centers for Disease Control and Prevention (CDC)
        Outpatient rehabilitation among stroke survivors—21 States and the District of Columbia, 2005.
        MMWR Morb Mortal Wkly Rep. 2007; 56: 504-507
        • Feldman S.R.
        • Ravis S.
        • Moran W.P.
        • Fleischer Jr, A.B.
        Patients seen in a dermatology clinic have unmet preventive health care needs.
        J Am Acad Dermatol. 2001; 44: 706-709
        • Kimball A.B.
        • Gladman D.
        • Gelfand J.M.
        • et al.
        • National Psoriasis Foundation
        National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
        J Am Acad Dermatol. 2008; 58: 1031-1042
        • Prodanovich S.
        • Ma F.
        • Taylor J.R.
        • et al.
        Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
        J Am Acad Dermatol. 2005; 52: 262-267